Single-molecule experiment

Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and Announces Emerging Drug Development Pipeline

Retrieved on: 
Thursday, June 1, 2023
Other Health, Pharmaceutical, Research, Oncology, Software, Finance, Hospitals, Genetics, Data Management, Professional Services, Science, Technology, Clinical Trials, Cardiology, General Health, FDA, Biotechnology, Health, Molecule, DSM-IV codes, DNA, Partnership, Therapy, General Grievous, Chromatin, Neurodegenerative disease, Cancer, PARP1, SMT, Protein, Acquisition, Patient, Engineering, Single-molecule experiment, Vaccine, Pharmaceutical industry, Eikon, IND

Lastly, Eikon has acquired a suite of preclinical assets from Cleave Therapeutics that address targets involved in protein homeostasis, DNA damage repair and chromatin remodeling, areas that have importance in cancer and in neurodegenerative disease.

Key Points: 
  • Lastly, Eikon has acquired a suite of preclinical assets from Cleave Therapeutics that address targets involved in protein homeostasis, DNA damage repair and chromatin remodeling, areas that have importance in cancer and in neurodegenerative disease.
  • “With the acquisition of these very different clinical assets, Eikon has taken an important step in building a diverse portfolio, at different stages of the development cycle, which address significant unmet medical needs.
  • As part of its agreement with Impact Therapeutics, Eikon will work to bring the IND-ready asset IMP1734, a highly selective PARP1 inhibitor, into clinical development.
  • Impact CEO Sui Xiong Cai, Ph.D., said, “The Eikon team brings years of experience in oncology to the development of these important assets.

ONI Releases New Extracellular Vesicle Imaging Consumable Kit at the 10th Annual Meeting of the International Society for Extracellular Vesicles (ISEV2021)

Retrieved on: 
Tuesday, May 18, 2021
Technology, Medical devices, Photography, Software, Biotechnology, Other Health, Health, Data management, Optical, Video games, Microscopy, Creative works, Oxford Nanoimaging, Single-molecule experiment, Oni

\xe2\x80\x9cAt ISEV2021, we are highlighting early access to our first consumable product, a plug-and-play solution that can be easily integrated into the workflow for single-molecule characterization of EVs.

Key Points: 
  • \xe2\x80\x9cAt ISEV2021, we are highlighting early access to our first consumable product, a plug-and-play solution that can be easily integrated into the workflow for single-molecule characterization of EVs.
  • ONI\xe2\x80\x99s first product, the Nanoimager, is a desktop-sized, single molecule microscopy platform capable of visualizing, tracking and imaging individual molecules in living cells.
  • ONI was founded in 2016 as a spin-out of Oxford University and has its headquarters in San Diego.
  • For more information, visit oni.bio and follow ONI on Twitter @oniHQ and LinkedIn @ONI .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005726/en/\n'

LUMICKS Raises $93 Million in Series D Financing

Retrieved on: 
Friday, April 16, 2021
Branches of biology, Physical sciences, Natural sciences, Molecular biology, Biophysics, Microscopy, Cell biology, Spectroscopy, Single-molecule experiment, Optical tweezers, Fluorescence microscope, Tweezers

The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team.

Key Points: 
  • The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team.
  • With this fundraising, we believe LUMICKS is well positioned to drive significant growth of our Dynamic Single-Molecule platform and further accelerate the commercial adoption of the industry-changing z-Movi solution.
  • It builds on LUMICKS\' rapid innovation, anchored by its Dynamic Single-Molecule franchise that is expanding access to and use cases for single molecule force measurement.
  • Using LUMICKS\' groundbreaking C-Trap Optical Tweezers Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time.

LUMICKS Raises $93 Million in Series D Financing

Retrieved on: 
Friday, April 16, 2021
Branches of biology, Physical sciences, Natural sciences, Molecular biology, Biophysics, Microscopy, Cell biology, Spectroscopy, Single-molecule experiment, Optical tweezers, Fluorescence microscope, Tweezers

The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team.

Key Points: 
  • The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team.
  • With this fundraising, we believe LUMICKS is well positioned to drive significant growth of our Dynamic Single-Molecule platform and further accelerate the commercial adoption of the industry-changing z-Movi solution.
  • It builds on LUMICKS\' rapid innovation, anchored by its Dynamic Single-Molecule franchise that is expanding access to and use cases for single molecule force measurement.
  • Using LUMICKS\' groundbreaking C-Trap Optical Tweezers Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time.